CVS Health stock trades at EUR 76.94 with plus 0.18 percent

Published on 09/30/2026 at 10:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health stock stood at EUR 76.94 at Lang & Schwarz on September 30, 2026, plus 0.18 percent versus EUR 76.80. Q2 revenue rose 7.3 percent to USD 106.10 billion.

Moderner Apothekenverkaufsraum mit Apothekerin und Kundin vor Medikamentenregalen — CVS Health Corp. zeigt fotorealen Apothekenverkaufsraum mit Apothekerin und Kundin, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health Corp. (ISIN US1266501006) was trading at EUR 76.94 at Lang & Schwarz on September 30, 2026 at 10:09 a.m. CEST, plus 0.18 percent versus the prior close of EUR 76.80. The latest analyst signal is constructive, with UBS reiterating a Buy rating and a USD 118.00 price target on September 22, 2026.

Second quarter delivered a beat

According to Ticker Scout, CVS Health reported second-quarter 2026 results for the period ended June 30, 2026, with total revenue of USD 106.10 billion, up 7.3 percent year over year. Adjusted EPS was USD 2.58, compared with USD 1.81 in the prior-year quarter and USD 1.87 consensus, a USD 0.71 beat against the consensus figure.

The same filing summary shows GAAP diluted EPS of USD 2.31 versus USD 0.80 a year earlier. Operating income reached USD 4.70 billion, while year-to-date operating cash flow stood at USD 10.60 billion through June 30, 2026.

Guidance moved higher for 2026

CVS Health raised its full-year 2026 adjusted EPS guidance to USD 7.90-8.10 from USD 7.30-7.50, according to Ticker Scout. GAAP diluted EPS guidance rose to USD 6.84-7.04 from USD 6.24-6.44, and operating cash flow guidance increased to at least USD 11.50 billion from at least USD 9.50 billion.

For investors, the comparison between the USD 106.10 billion quarterly revenue and the USD 100.03 billion consensus estimate shows that the beat extended beyond earnings per share. The improved guidance also gives the June-quarter figures a forward connection, although the company operates across insurance, pharmacy services and retail pharmacy businesses with different margin profiles.

UBS keeps target above the market

Investing.com reported on September 22, 2026 that UBS kept its Buy rating and USD 118.00 target after a third-quarter management discussion. The report also said UBS viewed the discussion as better on the third-quarter Medicare Benefit Ratio, while Stars-related pressure remained a factor for the shares.

CVS Health had a market capitalization of USD 111.1 billion as of September 29, 2026. Its 52-week range was USD 69.51 to USD 110.68, placing the latest primary-market quote below the yearly high and leaving the current valuation sensitive to the pace of the insurance recovery.

CVS Health stock holds near EUR 77

CVS Health stock was trading at EUR 76.94 at Lang & Schwarz on September 30, 2026 at 10:09 a.m. CEST, plus 0.18 percent versus the EUR 76.80 prior close. The NYSE-listed stock was last at USD 87.10 on September 29, 2026 at 4:00 p.m. ET, while the euro quote provides the reference for investors in Germany.